Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium by Moayyeri, A et al.
Genetic determinants of heel bone properties:
genome-wide association meta-analysis and
replication in the GEFOS/GENOMOS consortium
Alireza Moayyeri1,2,{, Yi-Hsiang Hsu3,4,{, David Karasik3,4,{, Karol Estrada5,6,7,8,9,{, Su-Mei
Xiao10,11,{, Carrie Nielson14, Priya Srikanth14, Sylvie Giroux16, Scott G. Wilson2,17,18, Hou-Feng
Zheng19, Albert V. Smith20,21, Stephen R. Pye22, Paul J. Leo24, Alexander Teumer25, Joo-Yeon
Hwang28, Claes Ohlsson29, Fiona McGuigan30, Ryan L. Minster32, Caroline Hayward34, José M.
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Quantitative ultrasound of the heel captures heel bone properties that independently predict fracture risk and,
with bone mineral density (BMD) assessed by X-ray (DXA), may be convenient alternatives for evaluating osteo-
porosis and fracture risk. We performed a meta-analysis of genome-wide association (GWA) studies to assess
the genetic determinants of heel broadband ultrasound attenuation (BUA; n 5 14 260), velocity of sound (VOS;
n 5 15 514) and BMD (n 5 4566) in 13 discovery cohorts. Independent replication involved seven cohorts with
GWA data (in silico n 5 11 452) and new genotyping in 15 cohorts (de novo n 5 24 902). In combined random
effects, meta-analysis of the discovery and replication cohorts, nine single nucleotide polymorphisms (SNPs)
had genome-wide significant (P < 5 3 1028) associations with heel bone properties. Alongside SNPs within or
near previously identified osteoporosis susceptibility genes including ESR1 (6q25.1: rs4869739, rs3020331,
rs2982552), SPTBN1 (2p16.2: rs11898505), RSPO3 (6q22.33: rs7741021), WNT16 (7q31.31: rs2908007), DKK1
(10q21.1: rs7902708) and GPATCH1 (19q13.11: rs10416265), we identified a new locus on chromosome
11q14.2 (rs597319 close to TMEM135, a gene recently linked to osteoblastogenesis and longevity) significantly
associated with both BUA and VOS (P < 8.23 3 10214). In meta-analyses involving 25 cohorts with up to 14 985
fracture cases, six of 10 SNPs associated with heel bone properties at P < 5 3 1026 also had the expected direc-
tion of association with any fracture (P < 0.05), including three SNPs with P < 0.005: 6q22.33 (rs7741021), 7q31.31
(rs2908007) and 10q21.1 (rs7902708). In conclusion, this GWA study reveals the effect of several genes common
to central DXA-derived BMD and heel ultrasound/DXA measures and points to a new genetic locus with potential
implications for better understanding of osteoporosis pathophysiology.
INTRODUCTION
Bone structure in vivo has largely been evaluated using the
attenuation of a photon beam by hydroxyapatite, the principal
mineral in bone. This is positively related to the mass of hydroxy-
apatite in the path of the beam conventionally termed bone
mineral content and normalized to bone area to produce an
entity termed areal bone mineral density (BMD). To allow for
the reduced attenuation of the beam by overlying non-bone
tissues in central areas of the body, two photon beam energies
are used, resulting in a clinical technique termed dual-energy
X-ray absorptiometry (DXA), which at peripheral skeletal
sites is termed pDXA.
Over the past 60 years, ultrasonic material analysis has been
developed as a method of determining material properties of a
variety of structures. In the last 30 years, this methodology has
been applied to the in vivo assessment of bone structure and
fragility termed quantitative ultrasound (QUS). This consists
of the use of two separate ultrasound measurement techniques,
velocity of sound (VOS) and broadband ultrasound attenuation
(BUA). While much remains to be discovered about the exact
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physical determinants of QUS measures in the intact living cal-
caneum (1), cadaver studies have established a strong correlation
of such indices with bone quantity and trabecular structure (2).
Assessment of bone properties in the heel using QUS can
predict the risk of prevalent osteoporotic fractures, such as
those in the spinal vertebrae, comparably with DXA of the
spine or hip, the so-called gold standard clinical techniques
(3–5). Pearson correlation coefficients of heel QUS or pDXA
with central DXA of the hip or spine in population-based
studies are modest, typically in the range of 0.4–0.6 (6). More-
over, twin- and family-based studies have found genetic correla-
tions of the order of 0.3–0.6 and environmental correlations of
the order of 0.1–0.3 (7–9); yet relative risk estimates for fracture
using QUS are of similar magnitude to those derived from central
DXA (5,10,11). A recent meta-analysis showed that heel QUS
predicts risk of various fractures (hip, vertebral and any clinical
fractures) independently from hip BMD (12). Overall, these
results suggest that QUS of the calcaneum might capture add-
itional genetic determinants of bone structure beyond those asso-
ciated with central DXA.
A genetic contribution to osteoporosis is well established with
heritability estimates reaching 84% for central BMD (13), 74%
for heel QUS (7,14), 47% for bone loss (15), and 48% for
hip fracture (16). Previous genome-wide association (GWA)
studies have identified several chromosomal regions associated
with BMD in the hip and lumbar spine regions (17,18). The most
recent meta-analysis of GWA studies, performed in the context
of the Genetics Factors for Osteoporosis (GEFOS) consortium,
identified 56 genome-wide significant loci (32 new) associated
with hip/spine BMD (19). Fourteen out of these 56 BMD-
associated loci were also associated with fracture risk in a
case–control meta-analysis involving 31 000 fracture cases
among 133 000 individuals (19). Using data from the GEFOS
consortium, we aimed to extend the findings for central DXA-
derived BMD phenotypes by searching for single nucleotide
polymorphisms (SNPs) associated with heel QUS or heel
DXA measures across the human genome.
RESULTS
Participant characteristics are summarized in Table 1 and key
features of the discovery and replication phases are summarized
in Figure 1. In aggregate, the initial discovery phase meta-
analysis in 11 cohorts (Supplementary Material, Table S1) iden-
tified 42 loci of at least suggestive significance in relation to heel
bone measures, of which 9 overlapped with loci previously
found to be potentially associated with hip or spine BMD in
the GEFOS-BMD meta-analysis (19). Regional conditional ana-
lyses results were available for QUS measures from 9 cohorts
(comprising 7 of the initial discovery cohorts and a further
2 new cohorts that joined later). Based on the results of the con-
ditional analyses (that identified two secondary signals for the
QUS measures) and final combined meta-analysis of the uncon-
ditional results from all 13 discovery cohorts, a total of 25 inde-
pendent SNPs (Table 2) were selected for replication in the next
phase (i.e. in silico studies and de novo genotyping). Including
the two secondary signals, the selected SNPs comprise 15
SNPs that were primarily associated with either BUA or VOS,
and 12 SNPs that were associated with heel DXA BMD
(Table 2).
Associations between the 15 SNPs that were considered for
replication primarily on the basis of their association with heel
BUA or VOS are shown in Figure 2. The SNP characteristics
are summarized in Table 2. In the combined meta-analysis of
the discovery and replication cohorts using a random-effects
model, 9 SNPs showed genome-wide significant associations,
of which 7 were previously reported to be associated with
central DXA BMD (19). Two of the SNPs (rs7741021 and
rs2908007) also showed genome-wide significant association
with heel DXA BMD (Table 2). Three SNPs on chromosome
6q25.1 (rs4869739, rs3020331 and rs2982552) mapped to intron-
ic or regulatory regions around the ESR1 (estrogen receptor 1) and
CCDC170 (coiled-coil domain containing 170, previously known
as C6orf97) genes (Fig. 3), and five other SNPs mapped to loci
within or near previously identified osteoporosis susceptibility
genes, including 2p16.2 (SPTBN1, rs11898505), 6q22.33
(RSPO3, rs7741021), 7q31.1 (WNT16, rs2908007), 10q21.1
(DKK1, rs7902708) and 19q13.11 (GPATCH1, rs10416265).
We identified a new locus on chromosome 11q14.2 (TMEM135,
rs597319) significantly associated with both BUA and VOS
(P , 8.23 × 10214).
Subsidiary comparisons with fixed-effect meta-analysis
results (Supplementary Material, Table S2 and Figs S2 and S3)
suggested two additional genome-wide significant loci; one at
7p14.1 upstream of EPDR1 (rs6974574, P , 4.92 × 1028 for
BUA and VOS) and the other at 13q14.11 upstream of
AKAP11 (rs9533090, P ¼ 5.33 × 1028 for VOS), although
there was statistically significant between-study heterogeneity
in these two loci for the respective phenotypes (Supplementary
Material, Table S3), necessitating some caution in generalizing
the fixed-effect meta-analysis results. Figure 4 provides a com-
parison of the magnitudes of association of the 25 SNPs with
heel bone measures and central DXA BMD, suggesting general-
ly concordant associations in the overlapping genome-wide sig-
nificant or suggestive loci.
We further tested if the genome-wide significant or suggestive
genetic loci were associated with fracture risk based on data
available from 25 cohorts with up to 54 245 participants,
among whom there were 14 958 cases of any fracture (excluding
fractures of the skull and extremities, i.e. fingers and toes), 10
663 non-vertebral fractures and 3220 clinical vertebral fractures
(Supplementary Material, Table S4). Ten of 10 SNPs associated
with heel bone properties at P , 5 × 1026 showed the expected
directions of association with any fracture outcome based on the
point estimates (Fig. 5). Furthermore, 6 of these 10 SNPs showed
nominally significant (P , 0.05) associations with fractures, in-
cluding three SNPs with P , 0.005 (i.e. corrected for multiple
comparisons using Bonferroni method) at 6q22.33 (rs7741021),
7q31.31 (rs2908007), and 10q21.1 (rs7902708). Fixed-effect
meta-analysis gave similar results (Supplementary Material,
Fig. S4).
Supplementary Material, Figure S5 presents forest plots of the
study-specific results and summary estimates by random-effects
meta-analysis for the 15 SNPs that were considered for replica-
tion primarily on the basis of their association with heel BUA or
VOS in GWA discovery meta-analysis, suggesting generally
consistent results across cohorts for a majority of the SNPs. Sup-
plementary Material, Figure S6 shows the regional association
plots within a one megabase window of the top SNP in each
locus in the GWA discovery meta-analysis, demonstrating
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Table 1. Characteristics of studies that contributed to GWAS discovery and replication of SNP associations with heel QUS/DXA BMD measures
Stage\cohort Country Demographics Heel QUS/DXA BMD outcomes
N Females Age (years) Weight (kg) Height (cm) BUA (dB/MHz) VOS (m/s) Heel BMD (g/cm2)
(%) Mean (SD) Mean (SD) Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
GWAS discovery
EPIC UK 2630 56 62.1 (8.6) 80.5 (15.4) 167 (9) 2630 83 (19) 2630 1632 (40) – –
FHS USA 3229 58 64.6 (11.9) 76.8 (17.2) 166 (10) 3229 73 (21) 3225 1548 (38) – –
HKOS China 730 100 48.7 (15.4) 54.8 (10.4) 155 (7) 730 74 (22) 730 1551 (41) – –
NSPHS06 Sweden 495 55 51.4 (19.1) 71.9 (12.8) 164 (10) 495 96 (21) – – – –
RSI Netherlands 1615 54 66.5 (8.2) 74.3 (11.8) 169 (9) 1615 112 (13) 1615 1525 (37) – –
SHIP Germany 1198 54 58.0 (13.5) 80.2 (15.8) 168 (9) 1198 115 (15) 1198 1565 (35) – –
SHIP-TREND Germany 687 56 50.8 (13.6) 78.7 (15.1) 170 (9) 687 116 (14) 687 1571 (33) – –
TWINSUK1 UK 1701 100 46.2 (12.1) 65.8 (12.5) 163 (6) 1701 76 (18) 1701 1658 (49) – –
TWINSUK23 UK 1975 100 46.9 (12.5) 66.1 (12.2) 163 (6) 1975 76 (18) 1975 1653 (50) – –
H2SS Korea 1753 53 60.8 (6.6) 61.9 (10.0) 158 (8) – – 1753 1591 (45) – –
AGES Iceland 3179 58 76.4 (5.4) 75.8 (14.3) 167 (9) – – – – 3179 0.491 (0.152)
CroatiaKorcula Croatia 878 64 56.3 (14.2) 79.0 (14.2) 168 (9) – – – – 878 0.443 (0.098)
CroatiaSplit Croatia 499 57 49.3 (14.7) 80.6 (16.3) 172 (9) – – – – 499 0.459 (0.101)
Subtotal 20 569 66 60.3 (11) 73.3 (14.1) 165 (9) 14 260 86 (18) 15 514 1593 (42) 4556 0.478 (0.138)
In silico replication
AOGCa Australia/UKb 1955 100 69.6 (8.6) 69.6 (17.3) 158 (16) – – – – – –
B-PROOF Netherlands 1092 59 74.0 (6.7) 76.0 (12.4) 168 (9) 1092 69 (17) 1091 1535 (32) – –
HABC USA 1493 48 74.8 (2.9) 73.8 (14.3) 167 (9) 1493 73 (18) 1493 1541 (30) – –
MICROS Italy 588 45 46.0 (16.6) 70.2 (14.9) 167 (9) 588 73 (16) 588 1544 (29) – –
MrOS-USA USA 3925 0 73.9 (5.9) 83.1 (12.7) 175 (7) 3925 79 (17) 3925 1551 (30) – –
SOF USA 2103 100 80.1 (4.2) 66.3 (12.5) 158 (6) 2103 59 (17) 2103 1527 (30) – –
YFS Finland 1265 58 37.9 (5.0) 75.8 (15.5) 172 (9) 1265 80 (16) 1265 1559 (29) 1250 0.560 (0.110)
HCS-AUS Australia 986 49 66.2 (7.6) 79.4 (15.5) 166 (9) – – – – 986 0.538 (0.166)
Subtotal 13 407 52 69.2 (6.9) 75.4 (14.2) 167 (9) 10 466 73 (17) 10 465 1544 (30) 2236 0.550 (0.138)
De novo replication
AUSTRIOS-B Austria 448 85 83.6 (5.9) 62.0 (12.3) 156 (8) 448 90 (17) 448 1496 (36) – –
CABRIO-C Spain 1274 62 62.4 (9.2) 73.7 (13.1) 161 (8) 1274 70 (23) 1273 1545 (41) – –
CAIFOS Australia 1113 100 80.0 (2.6) 67.5 (12.1) 157 (6) 1113 101 (9) 1113 1516 (28) – –
CALEX-FAM Finland 983 79 37.0 (22.4) 64.3 (16.9) 164 (11) 983 83 (16) – – – –
EMAS Europeb 2870 0 59.9 (11.0) 83.1 (13.6) 173 (7) 2870 80 (19) 2870 1550 (34) – –
EPICNOR UK 5723 54 63.6 (9.2) 73.2 (12.4) 167 (9) 5723 79 (20) 5718 1638 (43) – –
EPOLOS Poland 684 56 53.4 (16.0) 73.2 (13.7) 166 (10) 684 112 (13) 684 1548 (35) – –
FLOS Italy 1000 84 59.8 (12.7) 64.8 (12.3) 163 (9) 1000 58 (7) 1000 1503 (83) – –
GEOS Canada 5495 100 55.8 (10.3) 65.4 (11.9) 158 (6) 5495 111 (10) 5495 1546 (32) – –
LASA Netherlands 894 51 75.6 (6.5) 74.2 (12.6) 166 (9) 894 71 (20) 894 1611 (44) – –
MrOS-SWE Sweden 1718 0 75.4 (3.2) 80.6 (12.0) 175 (7) 1718 81 (21) 1718 1555 (38) – –
OPRA Sweden 821 100 75.2 (0.1) 67.6 (11.3) 160 (6) 821 102 (10) 821 1523 (27) – –
OSTEOSII Greece 307 87 50.5 (12.6) 74.1 (15.7) 163 (7) 307 112 (16) 307 1556 (36) – –
PEAK25 Sweden 857 100 25.5 (0.2) 64.5 (11.2) 168 (6) 857 118 (11) 857 1575 (32) – –
SWS UK 715 100 29.7 (3.7) 72.4 (14.8) 163 (7) 714 72 (13) 715 1548 (27) – –
Subtotal 24 902 64 60.2 (10.0) 71.6 (12.7) 165 (8) 24 901 89 (16) 23 913 1568 (40) – –
Total 58 878 62 62.3 (9.7) 73.0 (13.6) 165 (8) 49 627 85 (17) 49 892 1570 (39) 6792 0.502 (0.138)
aThe AOGC cohort contributed to in silico lookups of SNP-fracture associations only.
bThe EMAS study comprises cohorts in Belgium, Estonia, Hungary, Italy, Poland, Spain, Sweden and UK.
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strong credible association signals for a number of SNPs under-
lying the loci selected for replication.
Subsidiary investigation of potential sex differences in the
association of SNPs and heel BUA or VOS measures did not
reveal convincing evidence of potentially important differences,
considering the secondary nature of the hypothesis and multiple
comparisons done (Supplementary Material, Fig. S7).
DISCUSSION
This is the first large-scale collaborative GWA study for heel
bone properties assessed by quantitative ultrasound and DXA
of the heel. Its conception was inspired by the observational
evidence of association of heel QUS measures and fracture
risk (12), independent of central DXA BMD measures (20),
demonstration of a reasonably high genetic heritability of heel
QUS measures (7), and suggestions of pleiotropic effects of
genes in the determination of bone phenotypes (8). Indeed,
consistent with the expected similarities and differences in the
physical properties of bone determined by DXA and QUS and
prior evidence of moderate genetic correlations between the
measures (7–9), we found evidence for some genetic loci
common to heel QUS measures and central DXA BMD as well
as a novel locus for heel QUS at 11q14.2 (TMEM135,
rs597319) that had not been previously identified as associated
with BMD or other bone phenotype.
Seven of nine genome-wide significant loci found in the
present study were previously reported to be associated with
BMD of the hip and/or spine (Fig. 4). This complements our pre-
vious findings (17–19) and lends support to the hypothesis of
partially shared genetic determinants between QUS and BMD
measures (7–9). A comparison of the standardized effect sizes
(Fig. 4) also revealed existence of some quantitative differences
for some SNPs. For example, in the 7q31.31 locus (WNT16), the
effect of rs2908007 on heel measures was about three times as
great as its effect on hip or spine BMD, supporting Karasik
et al.’s finding that there is significant pleiotropy in the effects
of genes on bone phenotypes at different measurement sites
(8). Similar quantitative differences were also observed for
rs7741021 at the 6q22.33 locus (RSPO3). In the absence of
bias and assuming minimal type II errors (i.e. adequate
power), such quantitative differences in effect sizes of SNPs at
different skeletal sites might indicate heterogeneity in genetical-
ly mediated responses of the skeleton to environmental stimuli,
including for example, ground reaction forces that are particular-
ly high at the heel but are dampened at more proximal sites such
as the lumbar spine (21,22).
Perhaps the most intriguing finding was that we identified
a new locus for bone phenotypes on chromosome 11q14.2
(rs597319) near the transmembrane protein 135 (TMEM135)
gene, that was genome-wide significant for both BUA and
VOS. The TMEM135 gene was first identified in a human lung
adenocarcinoma cell line cDNA library (23). It has been
Figure 1. Flow chart summarizing key features of the discovery and replication phases.
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Table 2. Summary of P-values for association of SNPs in 25 loci with heel BUA, VOS or heel DXA BMD in GWAS discovery/replication meta-analysis
Locus SNP Closest gene Genetic function Discovery P-valuesb Replication P-valuesb Combined P-valuesb
BUA VOS DXA BUA VOS DXA BUA VOS DXA
Combined P , 5 × 1028 9 cohorts, 14 258 participants 21 cohorts, 35 082 participants 30 cohorts, 49 335 participants
2p16.2 rs11898505 SPTBN1 Intronic, regulatory region 7.7831028 2.9231028 7.68×1021 6.66310212 1.10×1024 9.63×1022 4.24310213 6.25×1026 2.65×1021
6q22.33 rs7741021 RSPO3 Intronic, regulatory region 8.5231027 1.7231027 7.69×1026 1.19310218 2.54310221 1.49×1023 9.26310221 9.58310220 4.1131028
6q25.1 rs4869739 CCDC170 Intronic 5.25310210 4.75310211 7.73310210 1.02×1023 3.9231028 3.82×1021 1.9331029 2.64310218 1.21×1022
6q25.1 rs3020331c ESR1 Intronic 1.27×1022 7.94×1026 2.01×1024 3.04310210 3.79310217 1.95×1021 2.9131029 6.64310215 1.26×1023
6q25.1 rs2982552 ESR1 Intronic, regulatory region 2.87×1022 3.3131026 3.83×1024 6.16310217 1.14310218 1.00×1021 1.70310210 7.32310216 1.21×1024
7q31.31 rs2908007 WNT16 Upstream 8.59310221 5.02310223 4.31310211 1.31310222 2.06310239 3.47×1022 4.32310235 1.62310259 1.3431029
10q21.1 rs7902708 MBL2/DKK1 Intronic 8.23×1023 1.4631027 9.51×1021 1.0231028 6.9931029 2.60×1023 1.3031028 5.29310215 2.47×1021
11q14.2 rs597319 TMEM135 Intronic 2.62×1024 1.1831028 5.05×1023 2.01310212 2.70310217 2.20×1022 8.23310214 4.86310226 3.05×1024
19q13.11 rs10416265 GPATCH1 Non-synonymous coding 8.3031027 2.9931028 1.15×1021 5.8431028 2.92×1025 3.45×1021 2.37310213 4.08310212 6.72×1022
Combined P ≥ 5 x1028 9 cohorts, 14 258 participants 21 cohorts, 35 082 participants 30 cohorts, 49 335 participants
5p13.3 rs9292469 NPR3 Upstream 3.0931026 6.01×1023 9.27×1021 5.95×1021 1.69×1021 9.96×1021 1.43×1021 6.12×1021 9.42×1021
7p15.2 rs11520772 TAX1BP1 Intronic 9.7131027 4.84×1024 6.24×1021 8.43×1022 1.32×1021 5.48×1021 2.86×1024 7.07×1023 8.79×1021
7p14.1 rs6974574c EPDR1 Upstream 5.81×1023 1.34×1025 2.56×1024 2.51×1024 4.84×1023 7.31×1021 8.25×1025 3.89×1025 9.25×1023
7q11.23 rs38664 UPK3B Intronic 9.10×1024 1.5231026 6.60×1021 4.39×1022 1.58×1022 5.35×1021 3.25×1024 1.0231027 8.79×1021
13q12.3 rs3000634 USPL1 Upstream 2.10×1025 1.2731027 2.18×1021 6.80×1023 1.91×1021 5.38×1021 8.12×1021 8.00×1022 1.70×1021
13q14.11 rs9533090 AKAP11 Upstream 3.78×1022 5.04×1023 5.05310210 7.60×1023 2.44×1024 6.44×1021 1.02×1023 1.40×1025 6.97×1023
16q24.1 rs7188801 FOXL1 Upstream 3.32×1024 3.0931026 2.16×1022 3.91×1021 1.66×1022 5.48×1021 9.70×1023 7.62×1026 2.90×1022
9 cohorts, 14 258 participants 6 cohorts, 10 466 participants 15 cohorts, 24 723 participants
2p21 rs17032452 CAMKMT Intronic 8.73×1021 5.30×1021 1.7431026 5.49×1021 4.24×1021 3.59×1021 6.26×1021 9.67×1021 1.56×1023
3p14.2 rs6414591 C3orf67 Upstream 3.49×1021 2.39×1021 1.7231026 1.31×1021 9.13×1022 6.83×1021 7.86×1021 8.17×1021 9.22×1022
5q31.2 rs11959305 TGFBI Intronic 1.89×1022 1.82×1022 6.8431028 6.52×1021 2.80×1021 8.61×1021 8.47×1022 7.74×1023 1.15×1021
7p15.3 rs7787266 STEAP1B Intronic 4.08×1021 4.93×1021 2.5331026 2.93×1021 3.14×1021 6.21×1021 1.97×1021 2.70×1021 9.71×1023
9q21.33 rs10868487 GAS1 Downstream 6.10×1021 3.81×1021 2.3731026 2.61×1021 2.50×1021 7.03×1021 8.57×1021 7.46×1021 8.92×1022
13q31.1 rs9574655 SPRY2 Downstream 2.58×1021 1.38×1021 9.0931028 8.59×1021 6.43×1021 8.67×1022 5.81×1021 4.72×1021 3.50×1021
16q12.2 rs923220 IRX5 Upstream 1.24×1023 7.98×1023 6.0531027 7.85×1021 7.28×1021 9.34×1021 2.58×1022 3.95×1022 1.56×1022
20q11.22 rs3746429 EDEM2 Missense variant 4.42×1021 8.27×1021 3.8031027 2.07×1021 9.14×1022 3.35×1021 7.23×1021 3.93×1021 4.35×1024
21q22.2 rs2836789 FLJ45139 Upstream 1.56×1021 1.36×1022 1.5131026 2.09×1023 4.09×1022 5.07×1021 3.77×1023 2.27×1023 1.57×1023
P-values smaller than the genome-wide significance threshold (P , 5 × 1028) or suggestive significance threshold (P , 5 × 1026) are indicated in bold typefacea.
The association statistics for a new locus at chr 11q14.2 are italicized.
aThe P-values in the GWAS discovery are based on a fixed-effect meta-analysis model, while those in the replication and combined analyses are based on a random-effects meta-analysis model.
bThe number of cohorts and participants contributing to the analysis of each SNP at each stage slightly varied depending on quality control filters as well as successful imputation or de novo genotyping of the
particular SNP. Figure 1 and Supplementary Material, Figure S3 show the exact numbers that were available for each SNP at each stage for the confirmed loci.
cSecondary signals at the discovery phase following conditional analyses within the region (see Supplementary Material, Fig. S6 for the regional association plots).
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suggested that it is critically involved in the process of osteoblas-
togenesis from human multipotent adipose tissue-derived stem
cells (24). Marrow fat cells and osteoblasts share a common
stromal precursor and there is currently great interest in the
role of increased marrow fat in osteoporotic conditions and the
metabolic inter-relationships between these neighboring cell
types (25). In depth protein sequence analysis showed that
TMEM135 is a multi-transmembrane protein with seven
Figure 2. Summary of SNP associations with heel BUA or VOS in GWAS discovery meta-analysis and replication in independent samples of participants. The pooled
estimates in the GWAS discovery are based on a fixed-effect meta-analysis model, while those in the replication and combined analyses are based on a random-effects
meta-analysis model. Allele b indicates the effect allele, and the presence of two alleles in this column indicates that a proxy SNP with r2 . 0.8 (except for 16q24.1
locus for which r2 ¼ 0.6) was used for the replication analyses.
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transmembrane helices of high confidence. Homologies exist
between TMEM135 and the transmembrane region of frizzled-4
(24), a known component of the Wnt signaling pathway (26).
ENCODE project (27) data show that two SNPs in the intronic
region of TMEM135 and close to our lead signal (rs502580
and rs603140, both with high linkage disequilibrium with
rs597319 [r2 .0.92], and both highly associated with QUS out-
comes in our discovery cohorts [P  1.3 × 10– 7 for both]) are
associated with changes in MIF-1 and Cart1 motifs in osteoblast-
ic cell lines. Interestingly, both of these transcription factors
have been previously shown to be associated with skeletal devel-
opment and bone density (28,29). Furthermore, TMEM135 was
Fig. 2 Continued
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previously reported to be associated with longevity in Caenor-
habditis elegans models (30) as well as with longevity and
walking speed in humans (31). In summary, the associations
observed in our study might be the results of direct effects of
increased osteoblastogenesis on heel bone properties, or indirect
effects mediated through increased mechanical loading of the
calcaneum, associated with faster movements.
The other genetic loci with significant associations with heel
bone measures have previously been reported to be associated
with BMD or fractures. The ESR1 gene has been shown to be
related to osteoporosis susceptibility in both candidate gene
(32) and GWA studies (18,33). SNPs in SPTBN1 gene were
significantly associated with central DXA BMD in a previous
meta-analysis of GEFOS cohorts (18), as were SNPs in WNT16,
DKK1, and GPATCH1 genes in the recent GEFOS-BMD
meta-analysis (19). The RSPO3 gene has recently been suggested
as a bone-related locus by a GWA study of extreme low and high
BMD populations (34). The spectrin, beta, non-erythrocytic
Figure 3. Association of SNPs at chromosome 6q25.1 region with heel BUA, VOS, and heel DXA BMD in meta-analysis of discovery cohorts before (left column) and
after (right column) adjusting for the most significant SNP in the region (i.e. unconditional and conditional analyses respectively); as well as the unconditional results
for a novel locus for heel bone properties at chromosome 11q14.2. (The conditional analyses led to the identification of the highlighted secondary signal for association
of 6q25.1 with VOS. Conditional analyses results for heel DXA BMD were not available from the three relevant discovery cohorts. Color versions of the above figures
have been made available in Supplementary Material, Fig. S6.).
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1 (SPTBN1) gene located at chromosome 2p16.2 codes for the
b-subunit of spectrin, which is a molecular scaffold protein essen-
tial in linking plasma membrane to the actin cytoskeleton. Spec-
trin plays an important role in determination of cell shape,
positioning of transmembrane proteins, resilience of membranes
to mechanical stress, and organization of organelles and molecu-
lar traffic in cells. b-Subunits coded by SPTBN1 are responsible
for most of the spectrin-binding activity. Despite several GWA
studies confirming the association between SPTBN1 and osteo-
porosis (18,19,33,35), its role in bone pathophysiology is unclear.
The estrogen receptor 1 (ESR1) gene located at chromosome
6q25.1 codes for the estrogen receptor type 1 (also known as
ER-a). Two isoforms of estrogen receptors in humans (a and
b) are encoded by two different genes (ESR1 and ESR2) and
have distinct tissue and cell patterns of expression. Estrogen
receptor is a DNA-binding transcription factor that regulates
the activity of many different genes. Estrogen is well known
to inhibit bone resorption through both direct and indirect
actions on osteoclasts, and it is a major anabolic steroid in
bone, particularly evident in the establishment of peak bone
mass. Postmenopausal bone loss is complex, involving many
genetically regulated processes. After menopause, bone is lost
rapidly but variably for several years by most women as osteo-
clastic bone resorptive activity increases in association with
osteocyte apoptosis (36). In an osteoporosis GWA study by
deCODE Genetics in 2008 (33), several markers close to ESR1
were reported to show association with BMD, including intronic
variants and upstream SNPs close to CCDC170 (previously
known as C6orf97). This association was replicated in both
GEFOS-BMD meta-analyses (18,19), and we found three-
independent SNPs in this region associated with heel BUA and
VOS. Most recently, this locus has been shown to be more
associated with cortical volumetric BMD (as opposed to trabecu-
lar BMD), which implies a role of ESR1 products in osteoblasto-
genesis and cortical porosity (37).
The wingless-type MMTV integration site family, member 16
(WNT16) gene located at chromosome 7q31.31 is part of the
Wnt/LRP pathway, which is a known major anabolic pathway
in bone (38). The effects of activation of this pathway include
differentiation of mesenchymal precursors into osteoblasts,
osteoblast proliferation, bone mineralization, and avoidance
of osteoblast apoptosis, and inhibition of osteoclastogenesis
through effects on expression of OPG and RANKL. Other
members of this pathway such as LRP5, LRP4, SOST, WLS,
DKK1 and CTNNB1 have previously been associated with
BMD at genome-wide significance level (18,19,33,35).
The variant rs7902708 on chromosome 10q21.1 locates
between the MBL2 and DKK1 genes and is in close linkage
disequilibrium with another SNP in this locus (rs1373004,
R2 ¼ 0.87 in HapMap CEU population) that was previously
found to have a significant association with BMD and fracture
risk in GWA meta-analyses (19). Since the MBL2 (mannose-
binding lectin 2) gene product is active in the innate immune
system, it is more likely that these variants have a cis regulatory
effects on Dickkopf-1 (DKK1), which is a known Wnt signaling
pathway inhibitor (39). Several functional studies have showed
the role of DKK1 in osteolytic bone lesions in patients with
advanced multiple myeloma (40) and its inverse relationship
with bone mass has been shown in knockout mouse models
(41). A similar relationship to the Wnt signaling pathway has
also been proposed for the RSPO3 gene (21). Although
GPATCH1 was also found to be associated with hip and spine
BMD in a previous GEFOS meta-analysis (19), there is no func-
tional information about it in genomic databases.
Caution must be exercised in interpreting the results of the heel
DXA BMD analyses because there were less than 7000 partici-
pants contributing to the combined meta-analysis. The obtained
results, however, were consistent with the work of Portero et al.,
suggesting that heel DXA BMD and BUA measure comparable
properties of the calcaneum, which reflect the amount of bone
mineral in the field of view of the detector (2).
While the current study had limited statistical power in the
meta-analysis of SNP associations with fracture outcomes, it
was nevertheless encouraging to observe nominally statistically
Figure 4. Comparison of magnitudes of associations of 25 SNPs with heel bone
properties and central DXA BMD. The SNP associations with central DXA BMD
are based on lookup of previously published results from GEFOS.
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significant and expected directions of associations with fractures
for six SNPs associated with heel bone measures, including three
SNPs at 6q22.33 (rs7741021), 7q31.31 (rs2908007) and 10q21.1
(rs7902708) whose P-values for association surpassed the
multiple testing chance-corrected threshold of P , 0.005. The
concordant findings may, albeit indirectly, suggest that some
of the genetic susceptibility to fracture could partly be mediated
through bone properties (e.g. structural or material) captured by
QUS or DXA measures; but larger well-powered studies are
needed to appropriately assess such relevance.
In conclusion, the present GWA study reveals the effect
of several genes common to central DXA-derived BMD and
heel ultrasound/pDXA measures and points to a new genetic
locus with potential implications for better understanding of
osteoporosis pathophysiology. Quantitative differences seen in
the standardized effect sizes of some SNPs at different skeletal
sites are potentially indicative of heterogeneity in genetically
mediated responses of the skeleton to environmental stimuli, in-
cluding ground reaction forces that are particularly high at the
heel than at central sites.
MATERIALS AND METHODS
Study subjects and measurements
The GEFOS consortium is an international collaboration of
investigators dedicated to identify the genetic determinants of
osteoporosis (http://www.gefos.org/). In particular, the GEFOS
Figure 5. Per-allele odds ratios for association with fracture risk for 10 SNPs that were associated with heel BUA, VOS or heel DXA BMD at P , 5 × 1026 in com-
bined meta-analyses using a random-effects model. The pooled estimates are based on a random-effects meta-analysis model. FXANY ¼ any fracture;
FXNONVERT ¼ non-vertebral fracture; FXVERT ¼ vertebral fracture. Allele b indicates the effect of allele, and the presence of two alleles in this column indicates
that a proxy SNP with r2 . 0.8 was used for the replication analyses.
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consortium extended the breadth of its predecessor, the Genetic
Markers for Osteoporosis (GENOMOS) consortium, into
meta-analysis of GWA discovery studies. In the current
GEFOS/GENOMOS project, we performed GWA discovery
and replication of genetic loci associated with heel bone proper-
ties, including QUS (measures: BUA and VOS) and DXA
(measure: heel BMD).
The discovery phase comprises 13 cohort studies with GWA
data and relevant heel bone phenotypes (including BUA in 14
260 participants from 9 cohorts; VOS in 15 514 participants
from 9 cohorts; and heel DXA BMD in 4556 participants from
3 cohorts) arising from populations across North America,
Europe and East Asia. Independent replication was performed
using summary results from seven cohorts with GWA data
(in silico n ¼ 11 452) and analysis of individual-level data
from 15 other cohorts in the GENOMOS consortium that were
centrally genotyped for candidate polymorphisms by the
Kbioscience laboratory in the UK (de novo n ¼ 24 902).
Characteristics of the study cohorts/participants are summarized
in Table 1. All studies were approved by institutional ethics
review committees at the relevant organizations and all partici-
pants provided written informed consent. Further descriptive
information about the participating cohorts is available from the
GEFOS/GENOMOS websites (http://www.gefos.org/?q=studies
and http://www.genomos.eu/index.php?page=cohorts).
Genotyping and imputation methods
All the discovery cohorts were genotyped using commercially
available Affymetrix (Affymetrix Inc., Santa Clara, CA, USA)
or Illumina (Illumina Inc., San Diego, CA, USA) genotyping
arrays. Quality control was performed independently for each
study according to standard manufacturer protocols and within
study procedures. To facilitate meta-analysis, each group per-
formed genotype imputation with IMPUTE or MACH software
using genotypes from the HapMap Phase II release 22, NCBI
build 36 (CEU or CHB/JPT as appropriate) as reference
panels. Each imputation software estimates an overall imput-
ation quality score for each SNP. These quality scores and
minor allele frequencies for up to 2.5 million SNPs available
from each cohort were considered in the meta-analysis.
Association analyses
In the discovery phase, each cohort conducted analyses accord-
ing to a standard prespecified analysis plan under an additive (i.e.
per allele) genetic model. Phenotypes for the association ana-
lyses were defined as the sex-specific standardized residuals
from linear regression of each outcome variable (BUA, VOS
or heel BMD) on age, age-squared, weight, height and
machine type (if more than one machine was used). The assump-
tion of normality of residuals in the linear regression model was
checked within each cohort for each phenotype and no devia-
tions were reported. The SNP–phenotype associations in each
study were adjusted for potential confounding by population
substructure using principal components as appropriate; pedi-
gree and twin-based studies—additionally—corrected for
family structure. The final results submitted to the Coordinating
Center for meta-analysis were the per-allele regression coeffi-
cients with corresponding standard errors and P-values for the
associations of up to 2.5 million SNPs and standardized residuals
of each outcome variable. Analysis of imputed genotypes used
either the dosage information from MACH or the genotype prob-
abilities from IMPUTE. The replication analyses used the same
analytical procedures as above where applicable (e.g. using
study-specific standardized residuals as outcomes).
Meta-analysis
Meta-analysis of the GWA discovery summary results was con-
ducted in two-independent collaborating centers (Cambridge,
UK and Boston, USA). Because of potentially limited power
to detect sex-specific associations, we prespecified the primary
analyses to involve meta-analysis of the pooled data (i.e. males
and females combined). Quality control filters applied for exclu-
sions of SNPs from the meta-analysis were: imputation quality
score of ,0.3 for MACH and ,0.4 for IMPUTE, average
minor allele frequency of ,1% across studies, and SNPs
missing from .50% of the cohorts contributing to each
outcome. Inverse-variance fixed-effects meta-analysis (using
METAL software) was conducted in the discovery set with
double genomic correction (42) to control for potential inflation
of the test statistics in individual studies and in the meta-analysis.
The genome-wide level of statistical significance was set at P ,
5 × 1028 and suggestive level of significance at 5 × 1028 ≤
P , 5 × 1026. There were no extreme genomic inflation
factors noted in the discovery phase studies or in the GWA
meta-analysis (Supplementary Material, Table S1). QQ plots
for the combined GWAS meta-analysis results are provided in
Supplementary Material, Figure S1.
To help refine the choice of SNPs to be taken forward for rep-
lication, conditional analyses were conducted within a 1 mega-
base window of the best-associated SNP in each locus in the
discovery cohorts, if there was more than one SNP with a sug-
gestive level of significance. These secondary analyses took
the SNP in the locus with the lowest P-value and conditioned
the analysis of all of the other SNPs in the locus by including it
in the regression models. In addition, for loci containing SNPs
previously associated with hip or spine BMD in GEFOS (19),
we performed additional conditioning on the nearby “BMD
SNP”.
The DerSimonian and Laird random-effects model was used
for meta-analysis of studies in the replication set and also in
the final combined analysis of the discovery and replication
studies (43). For each SNP included in the replication phase,
we meta-analyzed its association with all three phenotypes,
simply for completeness, but interpreted the findings while
taking into account the primary outcome that the SNP was asso-
ciated with in the discovery phase. Fixed-effect meta-analysis
results were used for subsidiary comparison. We also conducted
meta-analysis of the associations of SNPs with fracture out-
comes, using only SNPs that were associated with BUA, VOS
or heel DXA BMD at P , 5 × 1026 in the combined analyses,
to assess their potential relevance to this clinical outcome.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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